BCLS Fund III Investments, LP 13D and 13G filings for Dianthus Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 07:54 am Sale | 2024-12-31 | 13G | Dianthus Therapeutics, Inc. DNTH | BCLS Fund III Investments, LP | 2,689,707 8.800% | -302,321 (-10.10%) | Filing |
| 2024-02-02 4:32 pm Purchase | 2024-01-24 | 13G | Dianthus Therapeutics, Inc. DNTH | BCLS Fund III Investments, LP | 2,992,028 9.990% | 2,992,028 (New Position) | Filing |